Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study

INTRODUCTION: Emicizumab prophylaxis significantly reduces bleeding events; however, the associated impact on bone/joint health is unknown. AIM: To explore the effect of emicizumab prophylaxis on bone/joint health in people with haemophilia A (PwHA) without FVIII inhibitors enrolled in HAVEN 3 (NCT0...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiialainen, Anna, Niggli, Markus, Kempton, Christine L., Castaman, Giancarlo, Chang, Tiffany, Paz‐Priel, Ido, Adamkewicz, Joanne I., Levy, Gallia G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796488/
https://www.ncbi.nlm.nih.gov/pubmed/35905294
http://dx.doi.org/10.1111/hae.14642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796488/
https://www.ncbi.nlm.nih.gov/pubmed/35905294
http://dx.doi.org/10.1111/hae.14642

Ejemplares similares